首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 精神病 > 自閉症治療藥物:到2018年為止的開發平台評估與市場預測
產業/市場分類
製藥 (4816)
肥胖症治療 (44)
非專利藥 (129)
疫苗 (181)
神經疾病 (172)
骨頭疾病治療 (37)
動物用醫藥 (17)
處方藥 (156)
規章 (126)
感染疾病 (346)
精神病 (84)
製藥企業 (524)
糖尿病 (191)
癌症 (909)
藥物開發 (1449)
DDS (182)
OTC 非處方藥 (150)
市場調查報告書

自閉症治療藥物:到2018年為止的開發平台評估與市場預測

Autistic Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2018

出版商 GlobalData
出版日期 2011年10月 商品編碼 217225
內容資訊 英文 Pages: 67
價格
US $ 3500 PDF by E-mail (Single user license)
US $ 7000 PDF by E-mail (Site license)
US $ 10500 PDF by E-mail (Global license)


自閉症治療藥物:到2018年為止的開發平台評估與市場預測 是由出版商GlobalData在2011年10月所出版的。 這份英文市場調查報告書包含Pages: 67 價格從美金3500起跳。

簡介

自閉症(ASD)治療藥物市場在2010年達到了31億美金的規模。預測今後八年間將以年複合成長率7.5%擴大，到2018年將達到55億美金的規模。美國及主要歐洲各國ASD得病率的增加是推動市場的主要原因。再者，焦慮症及癲癇、憂鬱症等ASD的合併症亦對該市場的成長有所貢獻。

本報告提供自閉症的概要與診斷，概論治療方法，治療藥物市場的規模與2018年為止的預測，彙整主要各市場趨勢，開發平台，參與企業簡介等資料，為您概述為以下內容。

第1章 目錄

第2章 自閉症(ASD)治療藥物:簡介

  • 疾病概要
  • 免疫學
  • 病因及病理學
  • 症狀
  • 診斷
  • 治療與管理方法
  • 轉診途徑
  • 報告指南

第3章 市場特徵

  • 全球市場規模(2005∼2010年)
  • 全球市場預測(2010∼2018年)
  • 美國市場規模
  • 美國市場預測
  • 法國市場規模
  • 法國市場預測
  • 德國市場規模
  • 德國市場預測
  • 義大利市場規模
  • 義大利市場預測
  • 西班牙市場規模
  • 西班牙市場預測
  • 英國國市場規模
  • 英國市場預測
  • 日本市場規模
  • 日本市場預測
  • 推動市場的要素與阻礙要素
  • 機會與未滿足需求分析
  • 要點

第4章 競爭評估

  • 概要
  • 策略性競爭企業評估
  • 已上市的主要產品簡介
    • Abilify
    • Risperidone
  • 要點

第5章 各開發階段開發平台

  • 概要
  • 策略性開發平台評估
  • 各開發階段開發平台
  • 各作用機制開發平台
  • 臨床開發中的潛力治療藥物
  • 臨床開發中的潛力治療藥物分子簡介
  • 要點

第6章 臨床實驗藍圖

  • 各國
  • 各階段
  • 各治療狀況
  • 主要臨床實驗委託者
  • 參與計劃的主要企業

第7章 策略性評估

  • 影響未來市場的主要活動
  • 未來市場競爭的影響

第8章 未來的企業

  • 簡介
  • 企業簡介
    • Neuropharm Group PLC
    • Curemark LLC
    • Seaside Therapeutics
    • Cellceutix Corporation

第9章 專利與合作交易

第10章 附錄

圖表

目錄

Abstract

Summary

GlobalData, the industry analysis specialist, has released its new report, "Autistic Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Autistic Disorder Therapeutics market. The report identifies the key trends shaping and driving the global Autistic Disorder Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Autistic Disorder Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Autistic Disorder Therapeutics market. Its scope includes -

  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Autistic Disorder Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Autistic Disorder Therapeutics market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Autistic Disorder Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Autistic Disorder Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Autistic Disorder Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Autistic Disorder Therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global Autistic Disorder Therapeutics market landscape? - Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2. Autism Spectrum Disorder (ASD) Therapeutics: Introduction

  • 2.1 Disease Overview
    • 2.1.1 Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) Classification for ASD:
  • 2.2 Epidemiology
    • 2.2.1 Worldwide Prevalence
    • 2.2.2 Trends
    • 2.2.3 Gender Ratio
    • 2.2.4 Co-morbidity
    • 2.2.5 Quality of Life (QoL)
    • 2.2.6 Funding
    • 2.2.7 Economic Burden
  • 2.3 Etiology and Pathophysiology
  • 2.4 Signs and Symptoms
  • 2.5 Diagnosis
    • 2.5.1 Diagnosis of ASD Based on DSM-IV Classification:
  • 2.6 Treatment and Management Options
  • 2.7 Referral Pathway
  • 2.8 GlobalData Pipeline Report Guidance

3. ASD Therapeutics: Market Characterization

  • 3.1 ASD Therapeutics Market Size (2005-2010) - Global
  • 3.2 ASD Therapeutics Market Forecast (2010-2018) - Global
  • 3.3 ASD Therapeutics Market Size (2005-2010) - The US
  • 3.4 ASD Therapeutics Market Forecast (2010-2018) - The US
  • 3.5 ASD Therapeutics Market Size (2005-2010) - France
  • 3.6 ASD Therapeutics Market Forecast (2010-2018) - France
  • 3.7 ASD Therapeutics Market Size (2005-2010) - Germany
  • 3.8 ASD Therapeutics Market Forecast (2010-2018) - Germany
  • 3.9 ASD Therapeutics Market Size (2005-2010) - Italy
  • 3.10 ASD Therapeutics Market Forecast (2010-2018) - Italy
  • 3.11 ASD Therapeutics Market Size (2005-2010) - Spain
  • 3.12 ASD Therapeutics Market Forecast (2010-2018) - Spain
  • 3.13 ASD Therapeutics Market Size (2005-2010) - The UK
  • 3.14 ASD Therapeutics Market Forecast (2010-2018) - The UK
  • 3.15 ASD Therapeutics Market Size (2005-2010) - Japan
  • 3.16 ASD Therapeutics Market Forecast (2010-2018) - Japan
  • 3.17 Drivers and Barriers for the ASD Therapeutics Market
    • 3.17.1 Drivers for the ASD Therapeutics Market
    • 3.17.2 Barriers for the ASD Therapeutics Market
  • 3.18 Opportunity and Unmet Need
  • 3.19 Key Takeaway

4. ASD Therapeutics: Competitive Assessment

  • 4.1 Overview
  • 4.2 Strategic Competitor Assessment
  • 4.3 Product Profiles for the Major Marketed Products in the ASD Therapeutics Market
    • 4.3.1 Abilify (aripiprazole)
    • 4.3.2 Risperidone
  • 4.4 Key Takeaway

5. ASD Therapeutics: Pipeline Assessment

  • 5.1 Overview
  • 5.2 Strategic Pipeline Assessment
  • 5.3 ASD Therapeutics Pipeline - Pipeline by Phases of Development
    • 5.3.1 ASD Therapeutics - Phase III Pipeline
    • 5.3.2 ASD Therapeutics - Phase II Pipeline
    • 5.3.3 ASD Therapeutics - Phase I Pipeline
    • 5.3.4 ASD Therapeutics Market - Pre-clinical Pipeline
    • 5.3.5 Technology Trends Analytic Framework
  • 5.4 ASD Therapeutics Market - Pipeline by Mechanism of Action
  • 5.5 ASD Therapeutics - Promising Drugs under Clinical Development
  • 5.6 Molecule Profile for Promising Drugs under Clinical Development
    • 5.6.1 NPL-2008
    • 5.6.2 CM-AT
  • 5.7 Key Takeaway

6. ASD Therapeutics: Clinical Trials Mapping

  • 6.1 Clinical Trials by Region/Country (The US, the EU and Japan)
  • 6.2 Clinical Trials by Phase
  • 6.3 Clinical Trials by Trial Status
  • 6.4 Prominent Sponsors
  • 6.5 Top Companies Participating in ASD Therapeutics Clinical Trials

7. Strategic Assessment

  • 7.1 Key Events Impacting the Future Market
  • 7.2 ASD Therapeutics: Implications for Future Market Competition

8. ASD Therapeutics: Future Players

  • 8.1 Introduction
  • 8.2 Company Profiles
    • 8.2.1 Neuropharm Group PLC
    • 8.2.2 Curemark LLC
    • 8.2.3 Seaside Therapeutics
    • 8.2.4 Cellceutix Corporation

9. ASD Therapeutics: Licensing and Partnership Deals

10. ASD Therapeutics: Appendix

  • 10.1 Market Definitions
  • 10.2 Abbreviations
  • 10.3 Methodology
    • 10.3.1 Coverage
    • 10.3.2 Secondary Research
    • 10.3.3 Forecasting
    • 10.3.4 Primary Research
    • 10.3.5 Expert Panel Validation
  • 10.4 Contact Us
  • 10.5 Disclaimer
  • 10.6 Bibliography

List of Tables
  • Table 1: Prevalence of ASD in Major Markets
  • Table 2: National Institutes of Health, Autism Funding FY 2006-2009 ($m)
  • Table 3: Symptoms Based Drug Treatment Options for ASD
  • Table 4: ASD Therapeutics Market, Global, Revenue ($m), 2005-2010
  • Table 5: ASD Therapeutics Market, Global, Forecast ($m), 2010-2018
  • Table 6: ASD Therapeutics Market, The US, Revenue ($m), 2005-2010
  • Table 7: ASD Therapeutics Market, The US, Forecasts ($m), 2010-2018
  • Table 8: ASD Therapeutics Market, France, Revenue ($m), 2005-2010
  • Table 9: ASD Therapeutics Market, France, Forecasts ($m), 2010-2018
  • Table 10: ASD Therapeutics Market, Germany, Revenue ($m), 2005-2010
  • Table 11: ASD Therapeutics Market, Germany, Forecasts ($m), 2010-2018
  • Table 12: ASD Therapeutics Market, Italy, Revenue ($m), 2005-2010
  • Table 13: ASD Therapeutics Market, Italy, Forecasts ($m), 2010-2018
  • Table 14: ASD Therapeutics Market, Spain, Revenue ($m), 2005-2010
  • Table 15: ASD Therapeutics Market, Spain, Forecasts ($m), 2010-2018
  • Table 16: ASD Therapeutics Market, The UK, Revenue ($m), 2005-2010
  • Table 17: ASD Therapeutics Market, The UK, Forecasts ($m), 2010-2018
  • Table 18: ASD Therapeutics Market, Japan, Revenue ($m), 2005-2010
  • Table 19: ASD Therapeutics Market, Japan, Forecasts ($m), 2010-2018
  • Table 20: ASD Therapeutics, Phase III Pipeline, 2011
  • Table 21: ASD Therapeutics, Phase II Pipeline, 2011
  • Table 22: ASD Therapeutics, Pre-clinical Pipeline, 2011
  • Table 23: ASD Therapeutics, Most Promising Drugs Under Clinical Development, 2011
  • Table 24: ASD Therapeutics, Brief History of NPL-2008
  • Table 25: ASD Therapeutics Market, Clinical Trials by Country, 2011
  • Table 26: ASD Therapeutics, Clinical Trials by Phase, 2011
  • Table 27: ASD Therapeutics, Clinical Trials by Status, 2011
  • Table 28: ASD Therapeutics, Prominent Sponsors, 2011
  • Table 29: ASD Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011
  • Table 30: Neuropharm Corporation, ASD Pipeline Products, 2010
  • Table 31: Curemark LLC, ASD Pipeline Products, 2010
  • Table 32: Seaside Therapeutics, Autism Pipeline Products, 2011
  • Table 33: Cellceutix Corporation, Autism Pipeline Products, 2011
  • Table 34: ASD Therapeutics, Global, Deals, 2009-2011

List of Figures
  • Figure 1: ASD Recognition Based on Impairment
  • Figure 2: Major Brain Structures Implicated in ASD
  • Figure 3: Autism Symptoms Chart
  • Figure 4: ASD Referral Pathway
  • Figure 5: ASD Therapeutics Market, Global, Revenue ($m), 2005-2010
  • Figure 6: ASD Therapeutics Market, Global, Forecast ($m), 2010-2018
  • Figure 7: ASD Therapeutics Market, The US, Revenue ($m), 2005-2010
  • Figure 8: ASD Therapeutics Market, The US, Forecast ($m), 2010-2018
  • Figure 9: ASD Therapeutics Market, France, Revenue ($m), 2005-2010
  • Figure 10: ASD Therapeutics Market, France, Forecast ($m), 2010-2018
  • Figure 11: ASD Therapeutics Market, Germany, Revenue ($m), 2005-2010
  • Figure 12: ASD Therapeutics Market, Germany, Forecast ($m), 2010-2018
  • Figure 13: ASD Therapeutics Market, Italy, Revenue ($m), 2005-2010
  • Figure 14: ASD Therapeutics Market, Italy, Forecast ($m), 2010-2018
  • Figure 15: ASD Therapeutics Market, Spain, Revenue ($m), 2005-2010
  • Figure 16: ASD Therapeutics Market, Spain, Forecast ($m), 2010-2018
  • Figure 17: ASD Therapeutics Market, The UK, Revenue ($m), 2005-2010
  • Figure 18: ASD Therapeutics Market, The UK, Forecast ($m), 2010-2018
  • Figure 19: ASD Therapeutics Market, Japan, Revenue ($m), 2005-2010
  • Figure 20: ASD Therapeutics Market, Japan, Forecast ($m), 2010-2018
  • Figure 21: Opportunity and Unmet Need in the ASD Therapeutics Market, 2010
  • Figure 22: ASD Therapeutics, Strategic Competitor Assessment, 2011
  • Figure 23: ASD Therapeutics, Molecular Structure of Abilify
  • Figure 24: ASD Therapeutics, Molecular Structure of Risperidone
  • Figure 25: ASD Therapeutics, Pipeline by Phase of Development, 2011
  • Figure 26: ASD Therapeutics, Technology Trends Analytics Framework, 2011
  • Figure 27: ASD Therapeutics, Technology Trends Analytics Framework - Description, 2011
  • Figure 28: ASD Therapeutics, Pipeline by Mechanism of Action, 2011
  • Figure 29: ASD Therapeutics Market, Clinical Trials by Country, 2011
  • Figure 30: ASD Therapeutics, Clinical Trials by Phase, 2011
  • Figure 31: ASD Therapeutics, Clinical Trials by Status, 2011
  • Figure 32: ASD Therapeutics Market, Overall Sponsors, 2011
  • Figure 33: ASD Therapeutics, Prominent Sponsors, 2011
  • Figure 34: ASD Therapeutics Market, Drivers and Restraints, 2011
  • Figure 35: Implications for Future Market Competition in the ASD Market, 2011
  • Figure 36: ASD Therapeutics Market, Pipeline by Company, 2011
Back to Top